Morf Health vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF healthcare integration platform ('Segment + Zapier for healthcare') syncing patient data across clinical tools for 10K+ patients; YC S22 $3.5M Kindred Ventures-backed serving mental health and chronic care tech-enabled providers.
About
Morf Health is a San Francisco-based healthcare data integration and workflow automation platform — backed by Y Combinator (S22) with $3.5 million raised including a $3 million seed round led by Kindred Ventures in November 2023, with participation from Uncommon Ventures and Asymmetric Capital — providing tech-enabled healthcare providers (virtual mental health practices, nutrition programs, chronic disease management companies, and preventive care platforms) with an integration and automation layer that synchronizes patient data across their clinical and operational tools stack, described as 'Segment plus Zapier for healthcare.' Founded in 2022 and having onboarded 10,000+ patients through integrated workflows, Morf addresses the data fragmentation problem that plagues digital health companies operating across 5-15 specialized clinical tools that don't natively integrate.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.